Epiminder enrolls 100 people in its US trial of implanted long-term EEG monitoring for epilepsy
The randomized DETECT study is testing whether the under-the-scalp Minder system improves care decisions for people with drug-resistant epilepsy.
Epiminder says its US DETECT study has enrolled its 100th participant, ahead of the company’s November target. The randomized, controlled, blinded post-market study is testing whether continuous EEG recorded by the Minder system, which sits under the scalp, leads to better treatment decisions for people with drug-resistant epilepsy whose earlier EEG monitoring was inconclusive. It will enroll up to 210 people at up to 25 US sites, with 22 centers active now; participants are followed for six months. The company expects 125 participants by December and completion in the first half of 2027 (NCT07110337).
Minder received FDA De Novo authorization. Months of continuous recording could give doctors a far clearer seizure picture than short hospital stays or patient diaries, but the trial’s results are still to come.